These results represent a pivotal moment for people with obesity and the global scientific community as we look ahead to a new era of managing obesity and potentially reducing cardiovascular risks with semaglutide 2.4 mg. In the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 2.4 mg trials
Zhao XX, Gao WX, Gao YQ, Suo L, Chen J
References [1] NBC News
Eligibility typically includes a BMI 35 kg/m with weight-related comorbidities (with lower thresholds for some ethnic groups), and treatment is usually provided through specialist weight management services with specific duration limits
The online supply of these medical products to Ireland places their provenance outside the legitimate supply chain and therefore cannot be assured, the HPRA said, adding it was closely monitoring the situation
All nootropic peptide therapy should be conducted under physician supervision